US court refuses to block Sanofi-Aventis's insulin pen
This article was originally published in Scrip
Executive Summary
A US appeals court has affirmed a New Jersey judge's decision not to preliminarily enjoin sales of Sanofi-Aventis's Lantus (insulin glargine) SoloStar pre-filled disposable pen pending a decision on the merits of a patent dispute. Novo Nordiskalleged the SoloStar system infringed its patent on an insulin injection pen that requires less force to inject the medicine and prevents the user from dialing up a dose that exceeds the amount of insulin remaining in the pen. In February a New Jersey federal judge denied Novo Nordisk's request for a preliminary injunction, finding that the plaintiff failed to show a likelihood of success on the merits. The Federal Circuit Court of Appeals has now affirmed the ruling. The Lantus SoloStar pen entered the US market last year.
You may also be interested in...
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.
Eye On ODAC: Former Members, FDA’s Pazdur Talk Pre-Meeting Mindsets, Impact Of Sponsor’s Experts
Oncologic Drugs Advisory Committee reps and the Oncology Center of Excellence director go behind the scenes to discuss FDA interactions with panelists, how opinions can change during a meeting, and why the voting question is important.